For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Johnson & JohnsonJNJ US · Health Care · USD Current price$267.14as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 5Buy 11Hold 5Sell 222 analysts 3-year price (USD)Factor profileMulti-factor score 83 / 100 Market data
Business descriptionJohnson & Johnson (J&J) is a global healthcare giant operating in Pharmaceuticals and MedTech. It is a leader in a wide array of healthcare categories, including immunology, oncology, and vision care. Competitive moatJ&J possesses an unparalleled R&D budget and a highly diversified revenue stream. In Vision Care, it is the global leader in the contact lens market and a primary competitor in the intraocular lens (IOL) space. Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: $267.14 · Nov 20, 2026· USD
CFRA Ratingbuy
TBI Multi Score83
Theme Exposure
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: JNJBusiness description
Johnson & Johnson (J&J) is a global healthcare giant operating in Pharmaceuticals and MedTech. It is a leader in a wide array of healthcare categories, including immunology, oncology, and vision care.
Competitive moat
J&J possesses an unparalleled R&D budget and a highly diversified revenue stream. In Vision Care, it is the global leader in the contact lens market and a primary competitor in the intraocular lens (IOL) space.
Recent developments
- Vision Care Competition: J&J's PureSee IOL is projected to pressure Alcon AG's US PC-IOL franchise in 2026, highlighting J&J's aggressive innovation in the surgical eye care space.
- Portfolio Pivot: Following the spinoff of its consumer health division (Kenvue), J&J is now a more focused, higher-margin healthcare entity.
Investment risks / red flags
- Litigation: Like all major pharma companies, it faces ongoing legal risks related to product liability.
- Drug Pricing: Exposure to regulatory changes and pricing pressure in the US pharmaceutical market.
Market Data
Source: mkts.io · Nov 20, 2026, 14:01 UTC
Key Metrics
P/E (TTM)40.54
P/E (Fwd)23.01
Dividend2.01%
Beta0.20
52W High$290.25
52W Low$199.91
Analyst Consensus
5
11
5
2
Strong Buy5Buy11Hold5Sell222 analysts
Consensus Target$279.17
+4.5% upside
Calendar Events
Next EarningsJan 26, 2027
Ex-DividendNov 24, 2026
Dividend DateDec 8, 2026
Financials
Revenue$99.33B
Rev Growth5.90%
Earnings Growth-95.90%
Gross Margin67.77%
Op Margin26.59%
Profit Margin16.20%
EBITDA$34.50B
ROA8.46%
ROE20.02%
Rev/Share$41.25
Total Cash$17.23B
Total Debt$44.65B
D/E Ratio54.77
Free Cash Flow$18.50B
Op Cash Flow$26.16B
Current Ratio1.02
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 2.92 | $26.40B |
| +1q | 2.67 | $25.55B |
| 0y | 11.12 | $101.20B |
| +1y | 11.61 | $107.64B |
Earnings
Quarterly EPS
4Q2025
Est: 2.462.46Miss
1Q2026
Est: 2.682.70Beat
2Q2026
Est: 2.852.90Beat
3Q2026
Est: 2.522.59Beat
Annual
2022
Rev $94.94BEarn $17.94B
2023
Rev $85.16BEarn $35.15B
2024
Rev $88.82BEarn $14.07B
2025
Rev $94.19BEarn $26.80B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Oct 16, 2026 | Wells Fargo | main | Overweight |
| Oct 15, 2026 | Morgan Stanley | main | Overweight |
| Oct 14, 2026 | Leerink Partners | main | Outperform |
| Oct 14, 2026 | Wells Fargo | main | Overweight |
| Oct 14, 2026 | RBC Capital | main | Outperform |
| Oct 7, 2026 | Guggenheim | reit | Buy |
